The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.
Francois-Xaxier Mahon
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis
Michele Baccarani
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Michael J. Mauro
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Timothy P. Hughes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis
Giuseppe Saglio
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Michael Savona
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Incyte
Other Remuneration - Karyopharm Therapeutics
Tomasz K. Szczudlo
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Hans D. Menssen
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Christopher Hunt Keir
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Claudia Walasek
Employment or Leadership Position - Novartis
Andreas Hochhaus
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis